Usoro ọgwụgwọ CAR-T maka Neuroblastoma nlọghachite/naghachi azụ

GD2 CAR-T ọgwụgwọbụ ihe ọhụrụ immunotherapy nke na-agbanwe mkpụrụ ndụ ihe nketa mkpụrụ ndụ T nke onye ọrịa iji mata ma wakpo mkpụrụ ndụ neuroblastoma na-egosipụta GD2 antigen. Emebere ọgwụgwọ a maka ndị ọrịa na-alaghachi azụ azụ ma ọ bụ neuroblastoma nwere nnukwu ihe egwu ma gosipụta nsonaazụ ụlọ ọgwụ na-ekwe nkwa na nnwale.

• Ọnọdụ Ọrịa: Neuroblastoma nwere nnukwu ihe ize ndụ na ọrịa na-adịgide adịgide, nlọghachi azụ, ma ọ bụ na-aga n'ihu mgbe ọgwụgwọ mbụ gasịrị.

• Ihe ndị ọzọ: Ọrịa Metastatic, MYCN amplification, ma ọ bụ iguzogide usoro ọgwụgwọ.

Nzọụkwụ isi

1. Ndokwa n'ihu: Lymphodepletion tupu infusion.

2. Infusion: Usoro nhazi nke ọma nke mkpụrụ ndụ GD2-CAR-T (atụ aro: 10 × 10 ^ 6 CAR-positive T cell / kg).

3. Sochie: Ihe onyonyo mgbe niile (PET / CT, MRI) na nyocha ụmị ọkpụkpụ mgbe infusion gasịrị.

Nsonaazụ ụlọ ọgwụ

• Ọnụego nzaghachi: 33% nwetara mgbaghara zuru oke (CR), yana ọnụego nzaghachi zuru oke (CR+PR) nke 63%.

• Ịlanahụ: 3 afọ n'ozuzu nlanarị (OS) nke 60% na ndụ na-enweghị mmemme (EFS) nke 36% na usoro akwadoro.

• Profaịlụ nchekwa: Ọtụtụ ihe ọjọọ na-emekarị bụ njikwa ọkwa ọkwa 1-2 cytokine release syndrome (74%).

Uru Anyị

• Ọgbọ nke atọ ụgbọ ala: Ngalaba ngalaba mkpali abụọ (CD28 + 4-1BB) na-eme ka ike T-cell na nnọgidesi ike.

• Mgbanwe nchekwa: Mgbakwunye iC9 gene na-enye ohere ịchịkwa nsị ngwa ngwa ma ọ bụrụ na ọ dị mkpa.

• Ndekọ egwu egosipụtara: E gosipụtara ihe ịga nke ọma n'ime ule ụlọ ọgwụ nwere data nleba anya ogologo oge siri ike.